RESULTS OF INTRAVITREAL RANIBIZUMAB WITH A PRN REGIMEN IN THE TREATMENT OF EXTRAFOVEAL AND JUXTAFOVEAL NEOVASCULAR MEMBRANES IN AGE-RELATED MACULAR DEGENERATION
| Autor: | Ugo Menchini, Gianni Virgili, Daniela Bacherini, Lucia Finocchio, Giovanni Giacomelli, Ilaria Biagini, Fabrizio Giansanti |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Indocyanine Green
Male Vascular Endothelial Growth Factor A Fovea Centralis medicine.medical_specialty Visual acuity genetic structures Visual Acuity Angiogenesis Inhibitors Antibodies Monoclonal Humanized Pro re nata Ranibizumab Ophthalmology medicine Humans Fluorescein Angiography Coloring Agents Aged Retrospective Studies Aged 80 and over medicine.diagnostic_test business.industry General Medicine Diabetic retinopathy Middle Aged Macular degeneration medicine.disease Fluorescein angiography Choroidal Neovascularization eye diseases Regimen Treatment Outcome Choroidal neovascularization Intravitreal Injections Wet Macular Degeneration Female medicine.symptom business Tomography Optical Coherence medicine.drug |
| Zdroj: | Retina. 34:860-867 |
| ISSN: | 0275-004X |
| DOI: | 10.1097/iae.0000000000000007 |
| Popis: | Purpose: To evaluate the efficacy of intravitreal ranibizumab with a “pro re nata” regimen in the treatment of nonsubfoveal neovascular membranes secondary to age-related macular degeneration. Methods: Retrospective noncomparative case series. Thirty-one eyes with naive nonsubfoveal neovascularization secondary to age-related macular degeneration were consecutively enrolled and treated with ranibizumab intravitreal injections according to a pro re nata regimen. The follow-up was performed monthly up to 6 months and quarterly up to 2 years (25 patients). Early treatment diabetic retinopathy study best-corrected visual acuity and lesion size analysis with fluorescein angiography were recorded. Results: The mean baseline early treatment diabetic retinopathy study best-corrected visual acuity worsened from 20/40 (0.28 logMAR) at baseline to 20/50 (0.42 logMAR) at 1-year follow-up and 20/60 (0.53 logMAR) at 2-year follow-up. The mean lesions size nearly doubled from baseline at the 2-year follow up (1.19–2.47 mm2). Twenty-two patients had one or more recurrences at 1-year follow-up. All 25 patients developed a recurrence at 2 years with 7 cases developing a recurrence by 12 months. Twelve cases progressed to subfoveal lesions by the 24-month visit. Conclusion: Other regimens described in the literature might result in a more the satisfactory outcome using more frequent follow-up and more frequent intravitreal injections. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|